8-K: Mirion Technologies Announces Record Fourth Quarter and Full Year 2024 Financial Results; Reaffirms Full Year 2025 Guidance

Mirion Technologies reports record fourth quarter and full year 2024 financial results, with revenues up 10.4% in Q4 and GAAP net income showing a significant improvement, while also reaffirming full year 2025 guidance.

Summary

• Mirion Technologies announced its financial results for the fourth quarter and full year ended December 31, 2024.
• The company reported a 10.4% increase in revenue for the fourth quarter, reaching $254.3 million compared to $230.4 million in the same period in 2023.
• GAAP net income for the fourth quarter was $15.9 million, a significant improvement from a net loss of $14.5 million in the same period last year.
• Adjusted EBITDA for the fourth quarter increased by 14.1% to $69.6 million from $61.0 million in the prior year.
• GAAP net earnings per share for the fourth quarter was $0.07, compared to a net loss per share of $0.08 in the fourth quarter of 2023.
• Adjusted earnings per share for the quarter was $0.17, compared to $0.15 in the same period last year.
• Mirion reaffirmed its full year 2025 guidance, expecting total and organic revenue growth rates between 4.0% to 6.0% and 5.5% to 7.5%, respectively.
• Adjusted EBITDA for 2025 is expected to be between $215 million and $230 million.
• Adjusted Free Cash Flow for 2025 is projected to be between $85 million and $110 million.
• The company introduced initial Adjusted Earnings per Share guidance for 2025, estimating between $0.45 and $0.50 per share.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with record financial results and reaffirmed guidance, indicating strong performance and future growth potential. The management's comments further reinforce this positive sentiment.

Positives

• The company achieved record revenue, adjusted EBITDA, and adjusted EPS for both the fourth quarter and full year 2024.
• Mirion simplified its capital structure and significantly improved its net leverage during the year.
• Nuclear & Safety and Medical Groups grew fourth quarter organic revenue and enhanced their adjusted EBITDA margin performance compared to the same period last year.
• The company has approximately half of its expected 2025 revenue already in backlog.
• Mirion is advancing discussions on $300 $400 million of large order potential and sees increased opportunities to bid on other large deals.

Negatives

• The company's 2025 revenue growth is expected to include a foreign exchange rate headwind of approximately 190 basis points.
• Organic Revenue growth of approximately 5.5% 7.5% includes an approximately 30 basis point lasers business closure headwind from 2024.
• Adjusted EBITDA for 2025 includes a foreign exchange rate headwind of approximately $6 million.

Risks

• The company's guidance contains forward-looking statements, and actual results may differ materially due to known and unknown uncertainties and risks.
• These risks include changes in domestic and foreign business, market, economic, financial, political, and legal conditions.
• Other risks include developments in government budgets, public perception of nuclear radiation, ability to win and retain customers, risks related to governmental contracts, and IT system failures.
• The company also faces risks related to supply chain management, competition, strategic transactions, tax law changes, and legal claims.

Future Outlook

Mirion reaffirmed its full year 2025 guidance, expecting revenue growth, organic revenue growth, adjusted EBITDA, and adjusted free cash flow to increase. The company also introduced adjusted EPS guidance for 2025.

Management Comments

• Mirion's Chief Executive Officer Thomas Logan commented that the company is pleased to report record 2024 performance, with good momentum continuing into 2025.
• Logan stated that both fourth quarter and full year performance marked record revenue, record adjusted EBITDA, and record adjusted EPS, all while delivering on full year guidance.
• Logan noted that the company simplified its capital structure and significantly improved its net leverage during the year.
• Logan concluded that the company entered 2025 with approximately half of expected 2025 revenue in its backlog and is advancing discussions on large order potential.

Industry Context

Mirion operates in the radiation detection, measurement, analysis, and monitoring solutions market, serving the medical, nuclear, defense, and research end markets. The company's performance reflects the demand for its products and services in these sectors, particularly in nuclear safety and medical applications.

Comparison to Industry Standards

• It's difficult to provide a precise comparison without knowing Mirion's specific competitors and their results for the same period.
• However, companies like Teledyne Technologies, Flir Systems (now part of Teledyne), and various medical device manufacturers could be considered peers in certain segments.
• Mirion's revenue growth of 10.4% in Q4 and adjusted EBITDA increase of 14.1% would need to be benchmarked against these companies' performance to assess its relative standing.
• The reaffirmation of 2025 guidance is a positive sign, suggesting confidence in continued growth and profitability.

Stakeholder Impact

• Shareholders will likely react positively to the record financial results and reaffirmed guidance.
• Employees may benefit from the company's strong performance through potential bonuses or increased job security.
• Customers can expect continued investment in product development and service improvements.
• Suppliers may see increased demand for their products and services.
• Creditors can be reassured by the company's improved financial position and ability to meet its obligations.

Next Steps

• Mirion will host a conference call on February 12, 2025, to discuss its financial results.
• The company will continue to execute its 2028 long-range plan.
• Mirion will continue discussions on $300 $400 million of large order potential and pursue other large deal opportunities.

Key Dates